

	Total cohort (n=47)	IEI+ group (n=19)	IEI- group (n=28)	Chi2
<b>Categorical variables</b>	<b>No. (%)</b>	<b>No. (%)</b>	<b>No. (%)</b>	<b>P-value</b>
Males/Females	30/17 (64/36)	15/4 (79/21)	15/13 (54/36)	0.076
CVID	9 (19)	9 (47)	/†	/‡
ALPS	4 (8)	4 (21)	/†	/‡
DiGeorge Syndrome	1 (2)	1 (5)	/†	/‡
Unclassified IEI	5 (11)	5 (26)	/†	/‡
<b>Continuous variables</b>	<b>Mean [SD]</b>	<b>Mean [SD]</b>	<b>Mean [SD]</b>	<b>T-test</b>
Age at immune cytopenias onset (y)	8.6 [5.9]	9.7 [7.6]	7.9 [4.5]	0.348
Age at time of IEI diagnosis (y)	15.2 [7.1]	15.2 [7.1]	/†	/‡
Immune cytopenias follow-up duration (y)	7.0 [5.8]	11.3 [6.3]	4.0 [3.0]	<b>&lt;0.001</b>
Time between immune cytopenias onset and IEI identification (y)	5.4 [6.2]	5.4 [6.2]	/†	/‡

**Table 2** General characterization of cohort, IEI+ and IEI- groups (SD: standard deviation)

Abbreviations: ALPS, Autoimmune lymphoproliferative syndrome; CI, confidence interval; CVID, Common variable immune deficiency; IEI, Inborn errors of immunity; y, years.

† Data by definition not regarding IEI- group.

‡ No statistical analysis conducted on the data.